Phase III Trials

News Phase III Trials

• Abraxane plus gemcitabine improves survival in phase III study of patients with advanced pancreatic cancer

  Specialised Therapeutics Australia announced that a phase III clinical trial of breast cancer drug ABRAXANE® (nanoparticle albumin-bound paclitaxel) in combination with current standard of care gemcitabine in patients with advanced pancreatic cancer has demonstrated substantially improved survival t more

• Cardio3 BioSciences Receives Authorization for Phase III Clinical Trial in Regenerative Medicine for Heart Failure

  Cardio3 BioSciences (C3BS) announced it has received authorization from the Belgian Federal Agency for Medicines and Health Products (FAMHP) to begin its Congestive Heart failure Cardiopoietic Regenerative Therapy (CHART-1) European Phase III trial for C3BS-CQR-1 in Belgium. This represents a world more

• Genzyme Phase 3 Study of Oral Compound Eliglustat Tartrate for Gaucher Disease Meets Primary Endpoint

  Genzyme, a Sanofi company, announced that ENGAGE, the first Phase 3 trial of its investigational oral therapy, eliglustat tartrate, in previously untreated patients with Gaucher disease type 1, met its primary endpoint. Patients treated with eliglustat tartrate had a statistically significant improv more

Publications Phase III Trials

• Tumor treating fields: a new frontier in cancer therapy

  Tumor treating fields (TTFields) is a noninvasive, regional antimitotic treatment modality that has been approved for the treatment of recurrent glioblastoma by the U.S. FDA and has a CE mark in Europe. TTFields therapy delivers low‐intensity (1–3 V/cm), intermediate‐frequency (100–300 kHz), alter more

• Bevacizumab as front-line treatment for newly diagnosed epithelial cancer

  Ovarian cancer is the leading cause of death due to gynecological tumors. Despite the progress made during the last two decades in the surgery and chemotherapy of ovarian cancer, more than 70% of patients with advanced ovarian cancer will recur and die. Improvements in this field are coming from a b more

• Telbivudine treatment in chronic hepatitis B: experience from China

  Summary Telbivudine, one of the oral anti‐hepatitis B virus (HBV) nucleoside analogues, has been used for more than 5 yearsto treatHBeAg‐positive and negative chronic hepatitis B patients. This includes not only global Phase II and III trials, but also Chinese Phase III trials and several real‐w more

Market studies Phase III Trials

• D-Pharm Ltd. - Strategic SWOT Analysis Review

  D-Pharm LTD.(D-Pharm) is a specialty bio-pharmaceutical company. It is engaged in the design and development of innovative drugs for the treatment of the brain disorders. It has developed two unique platform technologies that generate lipid–like medicines which utilizes lipid specific mechanisms and more

• Japan Pharmaceuticals and Healthcare Report Q3 2012

  BMI View: The prospects for Japan’s pharmaceutical market over the medium term are very positive. The country has one of the largest pensionable populations, healthcare is readily accessible, the government appreciates investment in biomedical research and the regulatory regime balances the requirem more

• Sophiris Bio, Inc. (SHS) - Financial and Strategic SWOT Analysis Review

  Sophiris Bio, Inc. (SHS) - Financial and Strategic SWOT Analysis Review Summary Sophiris Bio, Inc. (Sophiris), formerly Protox Therapeutics Inc., is a biopharmaceutical company. It focuses on the research, development and commercialization of products for the treatment of urological diseases, such more

Websites Phase III Trials